Search results for: Innovation Policy Prize
Filter search results
How Should the World Pay for a COVID-19 Vaccine?
26 May 2020, 12:00am
…The hunt for a vaccine is on with the Coalition for Epidemic Preparedness Innovations (CEPI) funding projects around the world; a number of academic groups, including a team in Oxford…
The Lower Drug Costs Now Act and Pharmaceutical Innovation
1 September 2021
The US spends significantly more on healthcare per person than other wealthy countries. H.R. 3 is a recent policy proposal aimed at reducing national spending on prescription drugs, one component…
Anita Charlesworth
18 January 2023
…Panel. Anita is a member of the Council of the Royal Economic Society and University of Bath, Institute for Policy Research Advisory Board. She is Honorary Professor in the College…
Making the Most of Health Data to Deliver Pharmaceutical Innovation: What Are the Legal Barriers?
20 December 2018
OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation. As a society, we place a huge value on data: from…
Real Option Value and Path Dependence in Oncology Innovation
1 April 2014
Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations of the information available…
Innovation in Industry: a Factor for Growth
1 July 1969
Over the past few years there has been a growing concern with Britain’s record of industrial innovation based upon technology. This stems from two factors. Firstly, it is increasingly appreciated…
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
…Policy Brief. Center for Global Development. Available at https://www.cgdev.org/publication/estimating-japans-return-investment-ambitious-program-incentivize-new-antibiotics Silverman Bonnifield R and Towse A. 2022 Estimating UK’s Return on Investment from an Ambitious Program to Incentivize New Antibiotics. Policy…
Lotte Steuten
8 January 2019
Lotte Steuten is a health economist by training and primarily interested in health technology assessment and decision analytic modelling of health innovations. Alongside her position at OHE, Lotte is a…
Kahneman’s legacy in health economics
4 April 2024
…the issue of how to measure health states is a policy issue, which has to be decided as other policy issues are decided. The decision utilities and the experience utilities…